Regeneron Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 4/4
Regeneron Pharmaceuticals CEO'su Leonard Schleifer, Jan1988 tarihinde atandı, in görev süresi 38.33 yıldır. in toplam yıllık tazminatı $ 7.28M olup, şirket hissesi ve opsiyonları dahil olmak üzere 27.2% maaş ve 72.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.37% ine doğrudan sahiptir ve bu hisseler $ 1.69B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7.3 yıl ve 19.4 yıldır.
Anahtar bilgiler
Leonard Schleifer
İcra Kurulu Başkanı
US$7.3m
Toplam tazminat
| CEO maaş yüzdesi | 27.19% |
| CEO görev süresi | 38.3yrs |
| CEO sahipliği | 2.4% |
| Yönetim ortalama görev süresi | 7.3yrs |
| Yönetim Kurulu ortalama görev süresi | 19.4yrs |
Son yönetim güncellemeleri
Recent updates
Regeneron Pharmaceuticals: Q1 Beat Driven By Dupixent And Eylea HD Strength
Apr 29
REGN: Fair Outlook As Mixed Pipeline And Product Trends Shape Prospects
Regeneron Pharmaceuticals' updated analyst price target holds at $730, as analysts balance modest tweaks to growth, margins, and discount rate assumptions with recent Street research that broadly reiterates support for Dupixent, the broader pipeline, and capital return from the Sanofi repayment. Analyst Commentary Recent Street research around Regeneron points to a mixed but generally supportive tone, with several firms adjusting price targets and reiterating constructive views on Dupixent, the pipeline, and cash inflows from the Sanofi repayment.
REGN: Future Share Re Rating Seen Building On Underappreciated Immunology Pipeline
Analysts have modestly lifted their fair value estimate for Regeneron Pharmaceuticals to $1,030.49. The new estimate is supported by updated models that incorporate Street research pointing to stronger Dupixent contribution, an undervalued pipeline, and slightly higher assumed revenue growth, profit margins, and future P/E levels.
REGN: Expanding Immunology Franchise Will Support Future Upside Despite Concentration Risks
Analysts have raised their price targets on Regeneron, with the modelled fair value estimate moving from about $821.12 to $873.78 as they factor in stronger contributions from Dupixent, a higher revenue growth outlook, firmer profit margins, and a slightly lower assumed future P/E multiple. Analyst Commentary Bullish and cautious voices around Regeneron are both active, with recent research focused on how much of Dupixent's profit stream and the broader pipeline are already reflected in the share price.REGN: Fair Outlook As Pipeline Optionality Offsets Product And Competition Risks
Analysts have nudged their average price target for Regeneron higher into the low $900s, reflecting views that Dupixent profitability, indication expansion, and an undervalued pipeline, including Lynozyfic, are not fully reflected in the current share price. Analyst Commentary Recent research on Regeneron centers on whether the market is giving full credit to Dupixent and the broader pipeline versus risks tied to older products and future competition.
Regeneron Pharmaceuticals Inc. (REGN): The Biotech Stalwart – Defensive Growth Amid Biosimilar Headwinds in 2026.
Regeneron (REGN) is currently positioned as a defensive titan in the biotechnology sector, trading at $790.76 as of the March 2, 2026, close. While the broader healthcare index has faced pressure from regulatory pricing debates, Regeneron has demonstrated relative strength, maintaining a 1.2% year-to-date gain following a robust Q4 2025 earnings beat in late January.REGN: Fair Outlook As Future Pipeline And Spending Risks Remain
Analysts have raised their fair value estimate for Regeneron to $730 from $627, reflecting updated models that incorporate higher projected revenue growth, slightly stronger profit margins, and a modestly richer future P/E multiple, in line with a series of recent price target increases across the Street. Analyst Commentary Recent Street research on Regeneron has tilted positive, with a series of higher price targets from firms including Goldman Sachs, Citi, JPMorgan and others.REGN: 2026 Oncology Milestones Are Expected To Drive Share Re Rating
Analysts have nudged our Regeneron Pharmaceuticals fair value estimate higher to US$1,009.20 from US$995.67, reflecting updated price targets that lean on stronger modeled revenue growth assumptions, a modestly adjusted discount rate, slightly lower profit margin expectations, and a marginally lower future P/E multiple. Analyst Commentary Recent Street research around Regeneron has leaned firmly positive, with a cluster of bullish analysts lifting price targets across a tight time window.REGN: Pipeline Catalysts In 2026 Are Expected To Drive Re Rating
Analysts have lifted their fair value estimate for Regeneron Pharmaceuticals from US$890.00 to about US$995.67, reflecting higher modeled revenue growth and profit margins, alongside a slightly lower future P/E assumption and an updated discount rate. Analyst Commentary Recent research on Regeneron Pharmaceuticals has tilted clearly positive, with a series of higher price targets and supportive coverage pointing to confidence in the company’s execution, portfolio strength, and pipeline potential.REGN: Core Franchises And Pipeline Will Support Balanced Upside And Concentration Risks
Analysts have raised their fair value estimate for Regeneron Pharmaceuticals from about $781 to roughly $821. This reflects updated price targets that reference a slightly lower discount rate, modestly adjusted revenue growth assumptions, a small uptick in expected profit margins, and a higher future P/E multiple supported by recent bullish research calls from several major firms.REGN: Future Pipeline And Spending Risks Likely To Pressure Shares
Analysts have lifted their fair value estimate for Regeneron Pharmaceuticals to $627 from $543, citing faster expected revenue growth, improved long term profit margins, and a still compelling valuation multiple despite a modestly higher discount rate. Analyst Commentary Recent Street research on Regeneron highlights a generally positive stance on the company, with most firms reiterating or initiating Buy or Outperform ratings and lifting price targets following a strong third quarter.REGN: Core Franchises And Pipeline Will Support Measured Upside Amid Ongoing Risks
Regeneron Pharmaceuticals fair value estimate has been nudged higher to approximately $781 per share from about $768, as analysts factor in stronger medium term revenue growth, expanding profit margins, and a durable innovation led pipeline that supports higher long term earnings power despite modestly lower future multiple assumptions. Analyst Commentary Recent Street research on Regeneron reflects a generally constructive stance, with most firms reiterating or initiating positive ratings while modestly recalibrating price targets around execution risks and spending needs.REGN: Core Franchises And Upcoming Catalysts Will Drive Measured Upside Amid Risks
Regeneron Pharmaceuticals' analyst price target has been increased from approximately $753 to $768, as analysts highlight the company's resilient commercial base, innovative pipeline, and anticipated near-term contributions from core franchises and upcoming catalysts. Analyst Commentary Recent coverage of Regeneron Pharmaceuticals by Wall Street analysts reflects a broad consensus of confidence in the company's long-term growth drivers, while also acknowledging areas of risk that could impact future valuation and execution.Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Nov 19
REGN: Positive Trial Results And Approval Will Drive Continued Momentum
Regeneron's analyst price target has increased from approximately $735.72 to $753.17, as analysts cite better-than-expected quarterly results and continued strength across key product lines as drivers for the higher valuation. Analyst Commentary Bullish Takeaways Bullish analysts highlight the robust Q3 results, which surpassed expectations for both revenue and earnings.Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think
Nov 09Pipeline Strength And Recent Developments Will Drive Premium Potential Ahead
Regeneron's analyst price target increased from $722.20 to $735.72, reflecting improved earnings results and confidence in the company's drug pipeline, according to recent analyst commentary. Analyst Commentary Following Regeneron Pharmaceuticals' recent earnings results and updates across its drug pipeline, analysts have issued a series of updated price targets and recommendations.Broad Pipeline And Global Access Will Build Future Success
Regeneron Pharmaceuticals’ price target was raised to $722.20 as analysts cited continued outperformance and growth potential for Dupixent and Eylea, strong late-stage trial results in myasthenia gravis, and reinforced market leadership following competitor setbacks. Analyst Commentary Bullish analysts highlighted ongoing strength and growth potential for Dupixent and Eylea, with market share remaining dominant and robust prospects for Eylea HD.CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$4b |
| Dec 31 2025 | US$7m | US$2m | US$5b |
| Sep 30 2025 | n/a | n/a | US$5b |
| Jun 30 2025 | n/a | n/a | US$4b |
| Mar 31 2025 | n/a | n/a | US$4b |
| Dec 31 2024 | US$7m | US$2m | US$4b |
| Sep 30 2024 | n/a | n/a | US$5b |
| Jun 30 2024 | n/a | n/a | US$4b |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$8m | US$2m | US$4b |
| Sep 30 2023 | n/a | n/a | US$4b |
| Jun 30 2023 | n/a | n/a | US$4b |
| Mar 31 2023 | n/a | n/a | US$4b |
| Dec 31 2022 | US$7m | US$2m | US$4b |
| Sep 30 2022 | n/a | n/a | US$5b |
| Jun 30 2022 | n/a | n/a | US$6b |
| Mar 31 2022 | n/a | n/a | US$8b |
| Dec 31 2021 | US$6m | US$2m | US$8b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$4b |
| Dec 31 2020 | US$135m | US$1m | US$4b |
| Sep 30 2020 | n/a | n/a | US$3b |
| Jun 30 2020 | n/a | n/a | US$3b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$21m | US$1m | US$2b |
Tazminat ve Piyasa: Leonard 'nin toplam tazminatı ($USD 7.28M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 14.60M ).
Tazminat ve Kazançlar: Leonard 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Leonard Schleifer (72 yo)
38.3yrs
Görev süresi
US$7,280,549
Tazminat
Dr. Leonard S. Schleifer, M.D., Ph D., Co-founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988 and is its Board Co-Chair since June 2023. He ser...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 38.3yrs | US$7.28m | 2.37% $ 1.7b | |
| Co-Founder | 25.3yrs | US$6.95m | 1.15% $ 819.7m | |
| Executive VP of Finance & CFO | 2.3yrs | US$6.99m | 0.021% $ 15.3m | |
| Executive VP | 14.7yrs | US$7.46m | 0.042% $ 29.7m | |
| Executive VP of Research & Co-Chief Scientific Officer | 7.3yrs | US$8.48m | 0.051% $ 36.6m | |
| Executive VP and GM of Industrial Operations & Product Supply | 18.1yrs | US$8.78m | 0.035% $ 24.7m | |
| Senior Vice President of Quality Assurance & Operations | 1.3yrs | Veri yok | Veri yok | |
| Executive VP | less than a year | Veri yok | Veri yok | |
| Senior Vice President of Investor Relations & Strategic Analysis | no data | Veri yok | Veri yok | |
| Senior VP & Chief Compliance Officer | 3.3yrs | Veri yok | Veri yok | |
| Executive Vice President of Human Resources | 10.1yrs | Veri yok | Veri yok | |
| Senior Vice President of Public Policy & Government Affairs | 5.3yrs | Veri yok | Veri yok |
7.3yrs
Ortalama Görev Süresi
65.5yo
Ortalama Yaş
Deneyimli Yönetim: REGN 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.3 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 38.3yrs | US$7.28m | 2.37% $ 1.7b | |
| Co-Founder | 25.3yrs | US$6.95m | 1.15% $ 819.7m | |
| Lead Independent Director | 15.5yrs | US$775.42k | 0.0035% $ 2.5m | |
| Independent Director | 23.3yrs | US$725.42k | 0.016% $ 11.2m | |
| Independent Director | 34.9yrs | US$730.42k | 0.011% $ 7.8m | |
| Independent Director | 34.9yrs | US$715.42k | 0.0049% $ 3.5m | |
| Independent Director | 38.3yrs | US$730.42k | 0.033% $ 23.3m | |
| Independent Director | 9.3yrs | US$717.83k | 0.000010% $ 7.1k | |
| Independent Director | 3.6yrs | US$705.17k | 0% $ 0 | |
| Independent Director | 9.7yrs | US$720.42k | 0% $ 0 | |
| Independent Director | 9.7yrs | US$715.42k | 0.0017% $ 1.2m | |
| Independent Director | 2.7yrs | US$701.54k | 0% $ 0 |
19.4yrs
Ortalama Görev Süresi
72yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: REGN 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 19.4 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/04 04:20 |
| Gün Sonu Hisse Fiyatı | 2026/05/01 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Regeneron Pharmaceuticals, Inc. 52 Bu analistlerden 27, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| Eliana Merle | Barclays |